Difference between revisions of "Steele"
(Created page with " <span style="font-size:x-large;"><span style="line-height:normal">'''<span style="font-family:" times="" new="" roman",serif"="">No benefit from hyperbaric oxygen in amyotrop...") |
|||
| Line 1: | Line 1: | ||
| − | <span style="font-size:x-large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:x-large;"><span style="line-height:normal">'''<span style="font-family:">No benefit from hyperbaric oxygen in amyotrophic lateral sclerosis</span>'''</span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Clinical Bottom Line:</span>'''</span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family:"> 1. Both groups deteriorated at a similar rate.</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Citation/s:</span>'''<span style="font-family:">1. Steele J, Zutchi D, Bradley WD. Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic leteral sclerosis. Amyotrophic Lateral Sclerosis 2007;8:274-275</span></span></span> |
| − | <span style="font-size:large;"><span style="font-family: | + | <span style="font-size:large;"><span style="font-family:">'''Lead author's name and fax:''' Walter Bradley wbradley@med.miami.edu</span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"> </span></span><span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"> </span></span><span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Three-part Clinical Question:</span>'''<span style="font-family:">For patients with amyotrophic lateral sclerosis, does the administration of hyperbaric oxygen, compared to normal care, result in improved measures of ALS severity?</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Search Terms:</span>'''<span style="font-family:">Amyotrohic lateral sclerosis; </span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"> </span></span><span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"> </span></span><span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">The Study:</span>'''<span style="font-family:">Single-blinded randomised controlled trial with intention-to-treat.</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">The Study Patients:</span>'''<span style="font-family:">Patients meeting standard criteria for diagnosis of ALS and FVC >60% of expected.</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family:">Control group (N = 5 ; 5 analysed): 40 sessions of air breathing over 8 weeks for one hour daily at a maximum of 1.3 ATA.</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family:">Experimental group (N = 5 ; 5 analysed): As above but breathing 100% oxygen at 2 ATA.</span></span></span> |
<span style="font-size:large;"><span style="line-height:normal"> </span></span> | <span style="font-size:large;"><span style="line-height:normal"> </span></span> | ||
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">The Evidence:</span>'''</span></span> |
| − | <span style="font-family: | + | <span style="font-family:">Authors report both groups deteriorated at similar rates with HBO group at 81.5% of baseline at 20 weeks and the sham group 89.2% of baseline at 12 weeks. No other quantitative results.</span> |
| − | <span style="font-size:large;"><span style="line-height:normal"> </span></span><span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"> </span></span><span style="font-size:large;"><span style="line-height:normal"><span style="font-family:"> '''Comments:'''</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family:">1. Study was of two groups of five patients with HBO or sham treatment with allocation by toss of coin.</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family:">2. Patients were unaware of allocation when asked which group they were in.</span></span></span> |
| − | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal"><span style="font-family:">3. Study stopped early because there was no sign of slowed disease progression by 12 weeks analysis of the sham group and 20 weeks for the active group.</span></span></span> |
<span style="font-size:large;"><span style="line-height:normal"> </span></span> | <span style="font-size:large;"><span style="line-height:normal"> </span></span> | ||
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Appraised by:</span>'''<span style="font-family:">Mike Bennett m.bennett@unsw.edu.au ; Sunday, 15 November 2020</span></span></span> |
<span style="font-size:large;"><span style="line-height:normal"> </span></span> | <span style="font-size:large;"><span style="line-height:normal"> </span></span> | ||
| − | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family: | + | <span style="font-size:large;"><span style="line-height:normal">'''<span style="font-family:">Kill or Update By:</span>'''<span style="font-family:"> November 2026</span></span></span> |
| + | <p style="text-align: center;"> </p> <p style="text-align: center;">[[File:Sumhorsa.gif|center|Sumhorsa.gif]]</p> <p style="text-align: center;"><span style="font-size:xx-large;">[[Neuro_-_miscellaneous|BACK]]</span></p> | ||
Latest revision as of 00:12, 15 November 2020
No benefit from hyperbaric oxygen in amyotrophic lateral sclerosis
Clinical Bottom Line:
1. Both groups deteriorated at a similar rate.
Citation/s:1. Steele J, Zutchi D, Bradley WD. Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic leteral sclerosis. Amyotrophic Lateral Sclerosis 2007;8:274-275
Lead author's name and fax: Walter Bradley wbradley@med.miami.edu
Three-part Clinical Question:For patients with amyotrophic lateral sclerosis, does the administration of hyperbaric oxygen, compared to normal care, result in improved measures of ALS severity?
Search Terms:Amyotrohic lateral sclerosis;
The Study:Single-blinded randomised controlled trial with intention-to-treat.
The Study Patients:Patients meeting standard criteria for diagnosis of ALS and FVC >60% of expected.
Control group (N = 5 ; 5 analysed): 40 sessions of air breathing over 8 weeks for one hour daily at a maximum of 1.3 ATA.
Experimental group (N = 5 ; 5 analysed): As above but breathing 100% oxygen at 2 ATA.
The Evidence:
Authors report both groups deteriorated at similar rates with HBO group at 81.5% of baseline at 20 weeks and the sham group 89.2% of baseline at 12 weeks. No other quantitative results.
Comments:
1. Study was of two groups of five patients with HBO or sham treatment with allocation by toss of coin.
2. Patients were unaware of allocation when asked which group they were in.
3. Study stopped early because there was no sign of slowed disease progression by 12 weeks analysis of the sham group and 20 weeks for the active group.
Appraised by:Mike Bennett m.bennett@unsw.edu.au ; Sunday, 15 November 2020
Kill or Update By: November 2026
